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Prostate cancers generally acquire an androgen-independent
growth capacity with progression, resulting in resistance to anti-
androgen therapy. Therefore, identiﬁcation of the genes regulated
through this process may be important for understanding the
mechanisms of prostate carcinogenesis. We here utilized andro-
gen-dependent/independent transplantable tumors, newly estab-
lished with the ‘transgenic rat adenocarcinoma in prostate’
(TRAP) model, to analyze their gene expression using microar-
rays. Among the overexpressed genes in androgen-independent
prostate cancers compared with the androgen-dependent tumors,
glutathione S-transferase pi (GST-pi) was included. In line with
this, human prostate cancer cell lines PC3 and DU145 (androgen
independent) had higher expression of GST-pi compared with
LNCaP (androgen dependent) as determined by semiquantitative
reverse transcription–polymerase chain reaction analysis. To in-
vestigate the roles of GST-pi expression in androgen-independent
human prostate cancers, GST-pi was knocked down by a small
interfering RNA (siRNA), resulting in signiﬁcant decrease of
the proliferation rate in the androgen-independent PC3 cell line.
In vivo, administration of GST-pi siRNA–atelocollagen complex
decreased GST-pi protein expression, resulting in enhanced num-
bers of TdT mediated dUTP-biotin nick-end labering (TUNEL)-
positive apoptotic cells. These ﬁndings suggest that GST-pi might
play important roles in proliferation of androgen-independent
human prostate cancer cells.
Introduction
Prostate cancer is the most common cancer and the second most
common cause of death in men in the western world. Tumor growth
is initially androgen dependent (1). However, with progression,
androgen-dependent prostate cancers may become androgen indepen-
dent and resistant tohormone therapy (2). So far, there are no effective
clinical treatments for androgen-independent prostate cancer.
RNA interference is a powerful tool for downregulation of target
gene expression to investigate function (3). Recently, many studies
have provided support for RNA interference use as a therapy for
human diseases, including cancer (3–5). However, systems for clini-
cal delivery are controversial. Atelocollagen complexed with small
interfering RNA (siRNA) is reported to have resistance against nu-
cleases and can be efﬁciently transduced into cells in vivo (6–8). With
various routes of administration, siRNA–atelocollagen is effective for
gene silencing and efﬁcient inhibition of tumor growth (6). Thus, the
knock down of any key gene that can regulate androgen independence
might provide a tool for the treatment of patients with advanced
prostate cancers.
The transgenic rat adenocarcinoma in prostate (TRAP) features
introduction of the SV40 T antigen gene under probasin control, and
androgen-dependent prostate adenocarcinomas develop in 100% of
animals by 15 weeks of age, these being transplantable into the sub-
cutaneous back areas of nude mice (9). In the present study, we ﬁnally
established androgen-independent transplantable tumors by castration
of these mice. To identify genes mediating androgen dependence, we
compared gene expression between androgen-independent and -de-
pendent transplantable tumors derived from a TRAP rat prostate can-
cer, employing microarray analysis. Expression of selected genes
upregulated in the androgen-independent nude mice tumors was com-
pared with the expression of human orthologs in prostate cancer cell
lines LNCaP (androgen sensitive), DU145 and PC3 (androgen inde-
pendent) to assess whether data from rodent models can be extrapo-
lated to human cases. Furthermore using the bioluminescent PC3M-
luc-C6 (PC3ML) originating from PC3 and siRNA–atelocollagen,
effects of downregulation of the overexpressed genes were examined.
In this study, glutathione S-transferase pi (GST-pi) was investigated
as a gene, which is overexpressed in androgen-independent prostate
cancers of both human and rodent models.
Materials and methods
Establishment of an androgen-independent transplantable prostate tumor
Establishment of transplanted tumors. A large prostate tumor developing in
a lateral lobe of a 55-week-old TRAP rat was minced in Dulbecco’s modiﬁed
Eagle’s medium (Invitrogen Corp., Carlsbad, CA), and tissue fragments of
 8m m 3 were surgically transplanted to the back subcutaneous area of 5-
week-old male nude mice (Nippon SLC, Hamamatsu, Japan). Ten weeks after
the implantation, tumors were grafted to new mice.
Establishment of an androgen-independent strain. We obtained 10 mice that
carried 13th generation transplantable tumors derived from the prostate carci-
noma. Five of them were subjected for surgical castration. The tumors in the
castrated group did not grow for several weeks, but started to increase in size at
12 weeks after castration. These tumors were repeatedly grafted to new cas-
trated male mice every 10 weeks.
At euthanasia, tumors were excised and cut into slices of 2–3 mm thickness,
then ﬁxed in buffered formalin and routinely processed for embedding in
parafﬁn for histological evaluation with hematoxylin and eosin staining. For
immunohistochemical analysis, 3 lm thick sections were cut and incubated
with the ﬁrst antibody, and binding was visualized with a Vectastain Elite ABC
kit (Vector Laboratory, Burlingame, CA) and light hematoxylin counterstain-
ing. An SV40 large T antigen antibody (PharMingen, San Diego, CA) and an
androgenreceptor (AR) antibody(Signal Laboratory, Dedham,MA) were used
for conﬁrmation of the transgenic origin.
Total RNA extraction and quantitative reverse transcription–polymerase
chain reaction
Total RNA was extracted using Isogen (Nippon Gene, Tokyo, Japan) and
treated with DNaseI (Promega, Madison, WI). One microgram samples were
converted to complementary DNAwith avian myoblastosis virus reverse tran-
scriptase and oligo dT primers (TaKaRa, Otsu, Japan) in 20 ll of reaction
mixture and 2 ll aliquots were subjected to quantitative polymerase chain
reaction in 20 ll reactions using CYBR Premix Ex TaqTM (TaKaRa) and
a Light Cycler apparatus (Roche Diagnostics, Mannheim, Germany). The
ﬂuorescence intensity of double-strand-speciﬁc SYBR Green I, reﬂecting the
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of each elongation step and cyclophilin messenger RNA (mRNA) levels were
employed to normalize for the 5# sample complementary DNA content. Primer
sequences for rat Gstp2 were 5#-GCTCTTTAGGGCTTTATGGG-3# and 5#-
CTGTTTACCATTGCCGTTGA-3# and for human GST-pi were 5#-TGAAT-
GACGGCGTGGAG-3# and 5#-CCCTCACTGTTTCCCGTTGC-3#.
Atelocollagen and cell lines
Atelocollagen was supplied by Koken (Tokyo, Japan). Details were described
in a previous paper (6). Human prostate carcinoma cell lines (PC3, LNCaP
and DU145) were cultured in RPMI1640 (Invitrogen Crop. and Gibco, Carls-
bad, CA) with 10% fetal bovine serum. The bioluminescent human prostate
carcinoma cell line PC3M-luc-C6 (Xenogen, Alameda, CA) was cultured in
Eagle’s minimum essential medium (Invitrogen Corp.) supplemented with
10% heat-inactivated fetal bovine serum (Equitech-Bio, Kerrville, TX), non-
essential amino acids (Sigma–Aldrich, St.Loius, MO), L-glutamine (ICN, Ali-
soViejo, CA), 1 mM sodium pyruvate (Sigma–Aldrich), minimum essential
medium vitamin solution (Sigma–Aldrich) and 200 lg/ml zeocin
(Invitrogen Corp.). The cells were maintained in vitro at 37C in a humidiﬁed
atmosphere of 5% CO2.
siRNA preparation
Human GST-pi siRNA (Silencer predesigned siRNA, 2292) was purchased
from Ambion (Austin, TX). Silencer negative control #2 siRNA (Ambion)
withnosigniﬁcanthomologytoanyknownhumangeneswasusedasanegative
control siRNA. The ability of siRNA to silence GST-pi mRNA expression revel
was checked on the second day after transfection.
siRNA transfection and cell growth assay in vitro. PC3ML cells were plated at
5   104 cells per 6 cm well. One day after plating, cells were transfected
with 100 nM siRNA using DharmaFECT (Darmacon and GE Healthcare,
Buckinghamshire, England) according to the manufacturer’s protocol. For
monitoring inhibition of growth, cells were lysed (n 5 3) on days 2, 4 and 6
and then analyzed for luciferase activity (Bright-Glo Luciferase Assay System,
Promega). Data were normalized using results for vehicle-treated cells.
In vivo siRNA transfection and imaging of tumors. Nude mice-transplanted
PC3ML were administered with D-luciferin (150 mg/kg) (Promega) by intra-
peritoneal injection. Twenty minutes thereafter, photons from animal whole
bodies were counted using IVIS (Xenogen) according to the manufacturer’s
instructions. Details were described in the previous paper (7).
Western blotting
Frozen samples were lysed in LIPA buffer and 20 ml extracts were resolved
12% polyacrylamide gels and transferred to Hybond ECL (GE Healthcare).
The following antibodies were used for immunodetection: anti-GST-P (MBL,
Nagoya, Japan) and anti-beta actin (Sigma, St Louis, MI).
Statistical analysis
Statistical analysis was performed with the chi-square test and Student’s t-test
using the StatView-J 5.0 program (Berkeley, CA).
Results
Establishment of an androgen-independent transplantable prostate
tumor
A model-transplantable prostate adenocarcinoma line derived from
a TRAP rat was established with the methods described in Materials
and Methods. The tumors proved able to grow in castrated nude mice,
expressed SV40 large T antigen showing the TRAP rat origin and
were androgen independent with AR localization in the cytoplasm
(Figure 1).
Gstp2 expression in nude mice-transplanted prostate cancers
When mRNA expression data for androgen-independent and
androgen-dependent transplantable prostate carcinomas newly estab-
lished, were simply compared, Gstp2 was found to be 17.9 times
overexpressed in the androgen-independent nude mice tumors by
microarray analysis using a CodeLink rat whole-genome bioarray in
which Gstp1 was not included. The result was conﬁrmed by quanti-
tative reverse transcription–polymerase chain reaction using RNAs
extracted from ﬁve independent tumors of each type. Expression of
Gstp2 mRNA in the androgen-independent group was elevated .17-
fold (P , 0.0008) compared with the androgen-dependent group.
GST-pi expression in human prostate cancer cell lines
We also investigated the expression of human GST-pi, which is a ho-
molog of rat Gstp2 expressed in three human prostate cancer cell lines
(LNCaP, PC3 and DU145) and found higher expression in the PC3
and PC3ML cell lines (Figure 2A).
GST-pi expression and proliferation of PC3ML cells
In vitro. To silence GST-pi expression, human GST-pi siRNA was
applied into PC3ML cells and as a control, negative control siRNA.
As a result, drastic inhibition of proliferation activity was observed
only in the GST-pi siRNA case by the imaging anaysis (Figure 2B).
This result was conﬁrmed by histological observations. PC3ML
showed proliferating many cells becoming full conﬂuence on the dish
(Figure 2Ca), but GST-pi siRNA-treated PC3ML cells did not grow at
all, showing small number of living cells (Figure 2Cb).
In vivo. To examine the effect of silencing of GST-pi in vivo, PC3ML
cells were implanted subcutaneously into the backs of nude mice.
Eight mice for each group were administered with GST-pi siRNA–
atelocollagen complex or atelocollagen alone. Luciferase signaling
levels were slightly decreased, although the result was not statistically
signiﬁcant in the GST-pi siRNA-treated group at day 21 as compared
with the control group (Figure 3A and B). Final weights of tumors did
not show signiﬁcant differences (P 5 0.72, Figure 3C). We then ex-
amined the expression levels of GST-pi in the tumors by western
blotting (Figure 3D). Administration of GST-pi siRNA–atelocollagen
Fig. 1. Representative histological appearance of transplanted prostate
cancers in nude mice in the androgen-dependent group (A, C, E) and the
androgen-independent group (B, D, F). SV40 large Tantigen (SV40Tag) was
stained to conﬁrm origin from the TRAP rat prostate tumor (A, B).
Hematoxylin and eosin (HE) staining was performed to assess the degree of
differentiation (C, D). Castration effects were conﬁrmed by the localization
of AR. Non-castrated mice showed nuclear staining of the AR (E), whereas
castrated mice showed faint cytoplasmic staining (F), indicating inactive
receptor function.
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compared with atelocollagen alone from 1.271 ± 0.190 to
3.486 ± 0.450% (mean ± SD) (Figure 3Ea and Eb).
GST-pi staining was apparently observedinthe control tumortissue
(Figure 3Ec) in contrast to the siRNA-treated group with negative
staining, conﬁrming the effect of GST-pi siRNA–atelocollagen
complex effect.
Discussion
In this study, we found that GST-pi might participate in proliferation
of the androgen-independent human prostate cancer cell line, PC3.
We also showed transplantable tumors (10) in nude mice derived from
the TRAP rats to express Gstp2. Mammalian GSTs active in drug
metabolism are now classiﬁed into the alpha, mu and pi classes
(11). Pi-class GSTs have received particular interest in relation to
carcinogenesis (12–17). Gstp is well known to be markedly increased
in the early stages of rat liver carcinogenesis (18,19). Expression
levels of GST-pi have also been found to be elevated in many human
tumors (14,16,20,21).
The transplantable tumors in nude mice derived from the TRAP
cancer were poorly differentiated adenocarcinomas expressing SV40
large T antigen. They also expressed AR in their nuclei, but once
androgen levels were depressed by castration, the localization of
AR was changed to the cytoplasm, indicating a lack of function in
androgen-independent strains (see Figure 1). The mechanisms were
not clear and we tried to ﬁnd key factors by comparing mRNA ex-
pression of androgen-independent and -dependent transplantable tu-
mors. GST-pi was found to be the most signiﬁcantly overexpressed
gene in androgen-independent prostate cancers. There are many re-
ports of relations between GST-pi and prostate cancer (14,15,17,21–
30) and loss of expression by methylation of their promoter sequences
being found as an early event in human prostate carcinogenesis
(17,20,31–36). Using the mouse model of knockout Gstp1/Gstp2,
Ritchie et al. (37) have shown associated enhancement of lung carci-
nogenesis by chemical carcinogens. In skin tumorigenesis, similar
effects in the Gstp knockdown mice were reported by Hendersin
et al. (38).
These results in lung carcinogenesis of mice appear opposite to our
ﬁnding of growth suppression with decreased Gstp expression. In
contrast, GST-pi was reported to promote tumorigenesis of human
colon cancer cells (16) similar to the present contribution of GST-pi
to proliferation of androgen-independent prostate cancer cells. This
contradiction may be due to multiple functions of GST-pi or differ-
ences in knockdown methods between mice and rat or human models.
Here, we demonstrated that androgen-independent human prostate
cancer cell lines, DU145 and PC3, expressed GST-pi and silencing
caused signiﬁcant growth inhibition of PC3ML cells in vitro, but not
in vivo. The reason may be due to altered cell expression of GST-pi
invivo even in the atelocollagen-alone group and low efﬁciency of the
treatment (59.5% GST-pi-positive cells in the atelocollagen-alone
group to 49% in the GST-pi siRNA group).
In our results, the suppression due to siGST-pi resulted in statisti-
cally signiﬁcant apoptosis in the treated cells (P 5 0.0005 by Stu-
dent’s t-test) (Figure 3a and b). Inhibition effects on apoptosis by
GST-pi in human prostate cell lines were already reported by Lu
et al., suggesting an involvement of JNK and p38 activity (39). Arriazu
et al. (40) reported that expression of Gstp could be a response to
oxidative stress during carcinogenesis in the rat prostate. The ﬁndings
overall suggest that GST-pi might contribute to growth of androgen-
independent human and rat prostate carcinomas. The clinical rele-
vance of GST-pi overexpression in prostate carcinogenesis and
acquirement of androgen independence should now be clariﬁed invivo.
In summary, we identiﬁed Gstp2 in the nude mice model and GST-
pi in human prostate cancer cell line PC3 as responsible genes for
androgen-independent growth of prostate cancers. To identify more
precise mechanisms of androgen-independent growth converting
mechanism from androgen dependency, newly established nude mice
models of androgen dependent and independent with human prostate
cancer cell lines may be useful.
Fig. 2. The androgen-dependent human prostate cell LNCaP does not express GST-pi, in contrast to androgen-independent DU145, and especially PC3 and
PC3ML with high expression of GST-pi (A). Drastic growth inhibition was detected in the siGST-pi-treated PC3ML with reference to luciferase activity
statistically signiﬁcant ( P , 0.05) (B) and microscopic appearance with many proliferating cells in PC3ML treated with atelocollagen alone (Ca), whereas dead
cells in PC3ML treated with siGST-pi–atelocollagen (Cb), indicating proliferating activities of GST-pi.
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